New drugs for old.
The use of highly active antiretroviral therapy (HAART) has led to the emergence of viral isolates with resistance-associated mutations. Currently, new cases of highly resistant HIV infections associated with rapid progression to AIDS are being reported. The features of a new drug for HIV treatment must include selective potent activity against wild-type virus as well as against mutant virus that has been selected by the use of current antiretroviral treatment regimens. As patients in industrialised countries may live with HIV infection for decades, new drugs must also encourage adherence with simplified dosing regimens associated with favourable toxicity profiles. The replacement of older therapies with newer drugs that avoid cross resistance, even within the same class of antiretroviral, represents a new hope in retroviral targeting.
Winston
Alan
A
National Centre for HIV Epidemiology and Clinical Research, University of New South Wales, 376 Victoria Street, Sydney, Australia.
Stebbing
Justin
J
D019380:Anti-HIV Agents / Q000737:chemistry* / Q000494:pharmacology; D015195:Drug Design; D024882:Drug Resistance, Viral; D023581:HIV Fusion Inhibitors / Q000737:chemistry / Q000494:pharmacology; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D017320:HIV Protease Inhibitors / Q000737:chemistry / Q000494:pharmacology; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D018894:Reverse Transcriptase Inhibitors / Q000737:chemistry / Q000494:pharmacology
D019380:Anti-HIV Agents; D023581:HIV Fusion Inhibitors; D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors